In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins

被引:177
作者
MartinezMartinez, L
HernandezAlles, S
Alberti, S
Tomas, JM
Benedi, VJ
Jacoby, GA
机构
[1] MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, BOSTON, MA 02114 USA
[2] UNIV ISLAS BALEARES, DEPT BIOL AMBIENTAL, AREA MICROBIOL, PALMA DE MALLORCA, SPAIN
[3] UNIV BARCELONA, SCH BIOL, DEPT MICROBIOL, BARCELONA, SPAIN
关键词
D O I
10.1128/AAC.40.2.342
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Four Klebsiella pneumoniae isolates (LB1, LB2, LB3, and LB4) with increased antimicrobial resistance were obtained from the same patient, The four isolates were indistinguishable in biotype, plasmid content, lipopolysaccharide, and DNA analysis by pulse-field gel electrophoresis, Isolate LB1 made TEM-1 and SHV-1 beta-lactamases, Isolates LB2, LB3, and LB4 produced SHV-5 in addition to TEM-1 and SHV-1, MICs of cefoxitin, ceftazidime, and cefotaxime against LB1 were 4, 1, and 0.06 mu g/ml, respectively, MICs of ceftazidime against K. pneumoniae LB2, LB3, and LB4 were >256 mu g/ml, and those of cefotaxime were 2, 4, and 64 mu g/ml, respectively, MICs of cefoxitin against K. pneumoniae LB2 and LB3 were 4 mu g/ml, but that against K. pneumoniae LB4 was 128 mu g/ml. K. pneumoniae LB4 could transfer resistance to ceftazidime and cefotaxime, but not that to cefoxitin, to Escherichia coli. Isolate LB4 and cefoxitin-resistant laboratory mutants lacked an outer membrane protein of about 35 kDa whose molecular mass, mode of isolation, resistance to proteases, and reaction with a porin-specific antiserum suggested that it was a porin, MICs of cefoxitin and cefotaxime reverted to 4 and 2 mu g/ml, respectively, when isolate LB4 was transformed with a gene coding for the K. pneumoniae porin OmpK36, We conclude that the increased resistance to cefoxitin and expanded-spectrum cephalosporins of isolate LB4 was due to loss of a porin channel for antibiotic uptake.
引用
收藏
页码:342 / 348
页数:7
相关论文
共 51 条
[31]   INVIVO SELECTION OF A CEPHAMYCIN-RESISTANT, PORIN-DEFICIENT MUTANT OF KLEBSIELLA-PNEUMONIAE PRODUCING A TEM-3 BETA-LACTAMASE [J].
PANGON, B ;
BIZET, C ;
BURE, A ;
PICHON, F ;
PHILIPPON, A ;
REGNIER, B ;
GUTMANN, L .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (05) :1005-1006
[32]   NOVEL PLASMID-MEDIATED BETA-LACTAMASE (MIR-1) CONFERRING RESISTANCE TO OXYIMINO-LACTAMS AND ALPHA-METHOXY BETA-LACTAMS IN CLINICAL ISOLATES OF KLEBSIELLA-PNEUMONIAE [J].
PAPANICOLAOU, GA ;
MEDEIROS, AA ;
JACOBY, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) :2200-2209
[33]   EXTENDED-SPECTRUM BETA-LACTAMASES [J].
PHILIPPON, A ;
LABIA, R ;
JACOBY, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1131-1136
[34]   PROPERTIES OF PSE-2 BETA-LACTAMASE AND GENETIC-BASIS FOR ITS PRODUCTION IN PSEUDOMONAS-AERUGINOSA [J].
PHILIPPON, AM ;
PAUL, GC ;
JACOBY, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (03) :362-369
[35]   FACTORS DETERMINING RESISTANCE TO BETA-LACTAM COMBINED WITH BETA-LACTAMASE INHIBITORS IN ESCHERICHIA-COLI [J].
REGUERA, JA ;
BAQUERO, F ;
PEREZDIAZ, JC ;
MARTINEZ, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (05) :569-575
[36]   OUTBREAK OF CEFTAZIDIME RESISTANCE CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASES AT A MASSACHUSETTS CHRONIC-CARE FACILITY [J].
RICE, LB ;
WILLEY, SH ;
PAPANICOLAOU, GA ;
MEDEIROS, AA ;
ELIOPOULOS, GM ;
MOELLERING, RC ;
JACOBY, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) :2193-2199
[37]  
RICE LB, 1983, ANTIMICROB AGENTS CH, V37, P1061
[38]   PHYSICAL CHARACTERIZATION OF 10-R PLASMIDS OBTAINED FROM AN OUTBREAK OF NOSOCOMIAL KLEBSIELLA-PNEUMONIAE INFECTIONS [J].
SADOWSKI, PL ;
PETERSON, BC ;
GERDING, DN ;
CLEARY, PP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1979, 15 (04) :616-624
[39]  
Sambrook J., 1989, MOL CLONING LABORATO, V2nd
[40]   SELECTION OF MULTIPLE ANTIBIOTIC-RESISTANCE BY QUINOLONES, BETA-LACTAMS, AND AMINOGLYCOSIDES WITH SPECIAL REFERENCE TO CROSS-RESISTANCE BETWEEN UNRELATED DRUG CLASSES [J].
SANDERS, CC ;
SANDERS, WE ;
GOERING, RV ;
WERNER, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (06) :797-801